ACCESS Newswire

Millers Capital

3.6.2024 12:02:30 CEST | ACCESS Newswire | Press release

Share
European IPO Market Roars Back to Life: A Promising Start to 2024

SINGAPORE, SINGAPORE / ACCESSWIRE / June 3, 2024 / The IPO market has roared back to life in 2024, showcasing its strongest start since the 2021 boom. High-profile transactions involving companies like Galderma, Douglas, Puig, and CVC have signaled a resurgence, setting the stage for a robust year ahead.

Our analysis for the first quarter of this year highlights a notable recovery in Europe's IPO scene, with nearly €5 billion raised in the first quarter alone, according to S&P Global Market Intelligence. Private equity (PE)-backed IPOs have been particularly influential, accounting for three of the top five listings. This trend, along with a healthy pipeline, suggests a sustained recovery through the year. While consumer and luxury sectors have been prominent, the overall pipeline remains diverse. Let's explore the factors behind this recovery and what the rest of 2024 might hold.

Drivers of Europe's IPO Resurgence

The past few years have been tumultuous, with economic shocks post-pandemic, including geopolitical tensions and rising energy prices, leading to inflation and synchronized interest rate hikes by central banks. These factors created an uncertain market environment, widening the gap between investor and issuer expectations.

By late 2023, however, optimism returned as macroeconomic conditions stabilized. Declining energy costs, a rebound in global manufacturing, and inflation trends nearing the European Central Bank's 2% target have bolstered economic confidence. These developments have driven strong equity market performance, with the STOXX Europe 600 reaching record highs. Additionally, the volatility index has remained stable, supporting secondary equity markets.

These positive changes have rekindled investor confidence, paving the way for a functioning IPO market. This renewed confidence, coupled with a backlog of exit demand, has created an ideal environment for issuers and sellers.

Private Equity's Role in IPO Market Dynamics

Since 2021, macroeconomic challenges and rising interest rates have reshaped the PE exit landscape. IPOs had taken a backseat as PE firms held onto investments to avoid lower valuations, creating a backlog of maturing investments. PitchBook data indicates that global PE assets under management now exceed $5 trillion, highlighting substantial unrealized value.

The recent stabilization of equity markets has opened a window for more PE-backed IPOs. As pressure to realize value mounts, we anticipate increased activity in the IPO market for PE-backed assets. The overhang from 2021's PE-backed IPOs will likely drive follow-on equity issuance in 2024 and beyond.

As Thomas Gallagher, Director of Private Equity at Millers Capital Investment Pte Ltd., stated, "The resurgence of the IPO market provides an excellent opportunity for PE firms to unlock value in their portfolios, which had been on hold due to market volatility."

Global IPO Trends and Regional Variations

Globally, while Western IPO markets have reopened, IPO values in Q1 2024 were down 6% compared to Q1 2023, primarily due to a 48% drop in the Asia-Pacific region. Nonetheless, India's stock market continues to thrive, with $2 billion in IPOs in Q1 2024. The Middle East has also shifted focus from oil and gas to other industries, signaling a maturing market with broader appeal to international investors.

The performance of IPO markets in Europe and the U.S. is heavily influenced by global macroeconomic conditions, while regions like the Middle East and India are driven by local factors such as domestic growth.

Looking Ahead: The Future of IPOs in 2024 and Beyond

Optimism abounds for Western IPO markets through 2024 and into 2025, supported by a strong pipeline, robust market performance, lower volatility, and an improved inflation outlook. Successful IPOs in Q1 have set a positive tone, with a diverse range of issuers expected to support a vibrant IPO window in the latter half of the year.

However, geopolitical uncertainties and upcoming elections could temper this optimism. Innovation in IPO structuring, such as fixed-price offerings and smaller free floats, alongside alternative funding mechanisms like convertible instruments, will likely continue to evolve.

The London IPO market also stands at a pivotal point, with significant changes to the UK listing regime aimed at increasing its attractiveness. Interest from domestic and international companies suggests a favorable outlook for London listings.

Strategic Preparation: Key to IPO Success

For potential issuers, readiness is crucial to capitalize on the IPO window. The process, from strategic planning and readiness assessments to transaction execution and pricing, can take up to 24 months. Companies are focusing on improving their reporting environments, controls, and ESG disclosures to be "fit for listing."

With ample investable cash available, quality and stock fundamentals are paramount for IPO investors. Unlike the earlier boom driven by pre-revenue tech companies, current listings must demonstrate solid profitability. Planning for optionality, such as dual-track processes, can create tension in price discovery and align expectations with historical valuation levels.

Conclusion

The European IPO market is clearly on the mend, with a strong start to 2024 and positive aftermarket performance. As we approach the second half of the year, the market is expected to continue its recovery, contingent on the persistence of favorable conditions.

Contact:

Millers Capital Investment Pte Ltd.
Website: www.millers-capital.com
Media Relations: media@millers-capital.com

Singapore Office
21 Bukit Batok Cres.
25-78 Wcega Tower
Email: info@millers-capital.com
Phone: +65 3159 2522

Luxembourg Office
65 Avenue De La Gare 1611
Phone: +352 2843 1117

SOURCE: Millers Capital



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

RE Royalties Announces Second Tranche Investment of $800,000 in Solaris Energy's U.S. Distributed Generation Solar Portfolio9.2.2026 23:00:00 CET | Press release

All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / February 9, 2026 / RE Royalties Ltd. (TSX.V:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further USD $800,000 investment toward the purchase of royalties on two portfolios of distributed generation ("DG") solar projects located throughout the United States being developed by Solaris Energy Inc. ("Solaris"). The Royalty Purchase for Portfolio 1 totals USD $4.8 million, of which USD $3 million was funded at closing, as announced on January 7, 2026. The Company expects to fund the remaining USD $1 million by Q2 2026, subject to the satisfaction of applicable conditions. The Royalty Purchase for Portfolio 2 is subject to the completion of due diligence to the satisfaction of the Company, other customary closing conditions, and is expected to occur later in the year, bringing the total portfolio level royalty investment to USD $9 million. The Royalty Rate will be adju

UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities9.2.2026 06:00:00 CET | Press release

This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons Vesalic is pioneering a novel therapeutic to intercept and neutralise these toxins, potentially slowing or halting progression of monogenic and sporadic forms of ALS In addition, Vesalic has discovered a disease-specific alteration of the lipid composition in the membranes of exosomes circulating in the blood, and has developed a highly accurate biomarker-based technology to detect both monogenic and sporadic ALS Based on its novel biomarker discoveries, Vesalic is also applying its biomarker technology for other neurodegenerative diseases, including Alzheimer's and Parkinson's LONDON, UK / ACCESS Newswire / February 9, 2026 / Vesalic Limited, an early-stage neurodegenerative disease-focused biotech company, today emerged from stealth with the landmark discovery of a systemic process - largely

Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release

NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye